Related Experiment Video
Updated: Jul 7, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy
1Genitourinary Oncology Program, The Methodist Hospital Research Institute, Houston, TX 77030, USA. ramato@tmh.tmc.edu
Abstract:
Results of preclinical studies and clinical phase I/II trials suggest that the antisense oligodeoxynucleotide and DNA methyltransferase inhibitor MG98 can safely and effectively lead to reactivation of methylation silence tumor suppressor genes. It is possible that daily or continuous dosing of MG98 might be more active and less toxic than intermittent dosing. Combination of MG98 with other agents having completely different mechanisms of action seems reasonable. One clinical trial now under way is evaluating the use of MG98 in combination with interferon-alpha in patients with advanced renal cell carcinoma (RCC). Because of the current preclinical and clinical evidence, further trials of MG98 as therapy for RCC would be of interest.
Related Concept Videos
MicroRNAs
MicroRNAs
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Inhibitors of Bacterial DNA Synthesis
Experimental RNAi
